Vimarsana
Biggest News Aggregation in the World

Ciro Genomics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ciro Genomics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ciro Genomics Today - Breaking & Trending Today

MODERNA TO ACQUIRE ORICIRO GENOMICS - Vimarsana News

MODERNA TO ACQUIRE ORICIRO GENOMICS

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and OriCiro Genomics K.K., a pioneer in cell-free DNA synthesis and amplification technologies, today announced they have entered into a definitive agreement through which Moderna will acquire OriCiro for ...

Five sustainable tech companies in Japan building a better world - Vimarsana News

Five sustainable tech companies in Japan building a better world

Here are 5 sustainable tech companies companies in Japan to watch out for · EditForce · Green Earth Institute · OriCiro Genomics · Spiber.

Five industrial biotech companies making Japan more sustainable - Vimarsana News

Five industrial biotech companies making Japan more sustainable

Here are five industrial biotech companies that could help Japan to become more sustainable. · EditForce · OriCiro Genomics · Spiber

In Brief This Week: T2 Biosystems, HTG, Thermo Fisher, Dante Genomics, OriCiro Genomics, More - Vimarsana News

In Brief This Week: T2 Biosystems, HTG, Thermo Fisher, Dante Genomics, OriCiro Genomics, More

News items for the week of June 6, 2022.

OriCiro Genomics K.K.: OriCiro Announces Series B2 Financing to Advance Cell-Free DNA Technology for Innovative Therapeutics and Synthetic Biology - Vimarsana News

OriCiro Genomics K.K.: OriCiro Announces Series B2 Financing to Advance Cell-Free DNA Technology for Innovative Therapeutics and Synthetic Biology

TOKYO, June 6, 2022 /PRNewswire/ -- OriCiro Genomics, a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology, today announced